Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Safety and PK of Telpegfilgrastim in Healthy Women
NCT06893796Phase 1Completed
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegfilgrastim in preeclampsia (3 arms), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoints: Adverse Event, Blood Pressure and 15 more. Started Mar 2025; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT06893796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06893796.